Cyclerion Therapeutics (CYCN)
(Delayed Data from NSDQ)
$2.93 USD
-0.22 (-6.98%)
Updated Aug 30, 2024 09:30 AM ET
After-Market: $3.19 +0.26 (8.87%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.93 USD
-0.22 (-6.98%)
Updated Aug 30, 2024 09:30 AM ET
After-Market: $3.19 +0.26 (8.87%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.
Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.
Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.
Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
by Zacks Equity Research
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.